ADAMTS-18 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human ADAMTS-18 (Q8TE60), HEK293-expressed secreted metalloproteinase. Suited for fibronectin cleavage assays, ECM substrate studies, inhibitor screening, and antibody validation with matched TPB antibody RP-ADAMTS18.
Expression system
HEK293
Cat. #
REC-ADAMTS18

In stock

SKU
REC-ADAMTS18
$498.00

Target Overview

ADAMTS-18 (UniProt Q8TE60; gene ADAMTS18) is a secreted metalloproteinase of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family. The full-length human protein spans 1,221 amino acids and is classified under EC 3.4.24.-. Like other ADAMTS family members, ADAMTS-18 is processed and released into the extracellular space, where it acts on extracellular matrix (ECM) substrates. Published biochemical work has established fibronectin as a direct substrate: ADAMTS-18 cleaves fibronectin and negatively regulates fibronectin fibrillogenesis, placing it among the ECM-remodelling sheddases relevant to tissue organisation and matrix homeostasis (Barbiera et al., 2025, J Biol Chem). This recombinant is produced in HEK293 mammalian cells, a choice that supports native-like N-glycosylation and disulfide-bond formation — features important for the correct folding and activity of multi-domain secreted metalloproteinases. Researchers use this preparation in enzymatic activity assays with defined ECM substrates, in inhibitor IC50 determinations, and as a well-characterised positive control for antibody validation experiments. For researchers validating ADAMTS-18-specific antibodies by Western blot or immunoprecipitation, this recombinant protein serves as a defined loading control. It is directly cross-referenced to the matched Triple Point Biologics antibody reagent (SKU: RP-ADAMTS18), which has been validated for Western blot applications. Together, the recombinant and antibody provide a self-consistent reagent pair for studies requiring both enzymatic and immunodetection tools targeting ADAMTS-18.

Background

ADAMTS-18 belongs to the 19-member ADAMTS proteinase family, a group of secreted, zinc-dependent metalloendopeptidases characterised by a reprolysin-type catalytic domain, a disintegrin-like module, and one or more C-terminal thrombospondin type-1 repeat (TSR) motifs. These structural features direct the proteinases to the pericellular ECM environment, where they regulate matrix assembly, turnover, and signalling by processing specific substrates. ADAMTS-18 is localised to the extracellular space and ECM (UniProt Q8TE60). A central biochemical finding underpinning current ADAMTS-18 research is its capacity to cleave fibronectin and suppress fibronectin fibrillogenesis (Barbiera et al., J Biol Chem, 2025). Because fibronectin fibrillogenesis drives matrix assembly and cell adhesion, this activity positions ADAMTS-18 as a regulator of ECM architecture with downstream consequences for cell migration and tissue remodelling — contexts relevant to both normal physiology and pathological states under active investigation. ADAMTS18 has been studied as a research target in several disease contexts. In oncology, expression and mechanistic studies in endometrial cancer have examined its role in tumour biology (Li et al., J Mol Histol, 2026). The gene has also appeared in genetic studies of rare inherited conditions: a pedigree study of concurrent achromatopsia and MMAT syndrome identified ADAMTS18 variants in a multi-condition inheritance context (Aghasipour et al., Eur J Med Genet, 2025), consistent with earlier reports of ADAMTS18 variants in ocular and skeletal phenotypes. In cardiovascular research, serum ADAMTS-18 levels have been investigated as a potential circulating marker associated with functional outcome following acute ischemic stroke (Cui et al., J Atheroscler Thromb, 2026), suggesting the protein may be released or regulated in vascular injury settings. ADAMTS18 expression has additionally been reported in studies of endometrial receptivity (Nguyen et al., Hum Reprod, 2025). Across these research areas, recombinant ADAMTS-18 supports in vitro characterisation: defining substrate specificity, profiling small-molecule or endogenous inhibitors, and producing defined antigen for antibody validation. Because published studies span matrix biology, cancer biology, neurological outcome research, and reproductive biology, demand for well-characterised recombinant reagents that allow controlled, reproducible experiments continues to grow. Triple Point Biologics has been producing metalloproteinase and inhibitor antibody reagents since 1994; this recombinant is developed within that same framework of methodological rigour.

Applications

  • Fibronectin cleavage activity assay using SDS-PAGE or fluorescently labelled fibronectin substrate
  • ECM substrate selectivity profiling by mass spectrometry-based degradomics
  • Small-molecule inhibitor IC50 determination against purified recombinant ADAMTS-18
  • Antibody validation positive control for Western blot using matched TPB antibody RP-ADAMTS18
  • Immunoprecipitation input standard for anti-ADAMTS-18 antibody characterisation
  • Fibronectin fibrillogenesis inhibition assay in cell-free or cell-based matrix assembly systems
  • Binding interaction studies with candidate endogenous inhibitors or TSP-1 domain ligands by SPR or BLI

References

  1. Barbiera M et al. A disintegrin and metalloproteinase with thrombospondin motifs 18 (ADAMTS18) cleaves fibronectin and negatively regulates its fibrillogenesis. J Biol Chem. 2025. doi:10.1016/j.jbc.2025.110844. PMID: 41135673
  2. Cui T et al. Serum ADAMTS18 Levels at Admission Are Associated With 3-Month Functional Outcome After Acute Ischemic Stroke. J Atheroscler Thromb. 2026. doi:10.5551/jat.66202. PMID: 42270425
  3. Li X et al. The expression and mechanism of action of ADAMTS18 in endometrial cancer. J Mol Histol. 2026. doi:10.1007/s10735-026-10737-y. PMID: 41697416
  4. Aghasipour M et al. Concurrent inheritance of achromatopsia and MMAT syndrome in a pedigree: Genetic and clinical insights. Eur J Med Genet. 2025. doi:10.1016/j.ejmg.2025.105045. PMID: 40946907
  5. Nguyen TTN et al. Unveiling the molecular mechanisms of human platelet lysate in enhancing endometrial receptivity. Hum Reprod. 2025. doi:10.1093/humrep/deaf118. PMID: 40663777

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl₂, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Secreted; Extracellular matrix

Frequently Asked Questions

What molecular weight should I expect for recombinant ADAMTS-18 on SDS-PAGE or Western blot?

The full-length human ADAMTS-18 protein (UniProt Q8TE60) encodes 1,221 amino acids with a predicted unprocessed MW of ~136 kDa. However, this HEK293-expressed recombinant carries native-like N-glycosylation, so the apparent MW on SDS-PAGE typically runs higher — expect a diffuse band in the 150–175 kDa range under reducing conditions. Glycosylation heterogeneity can produce slight smearing, which is normal for heavily glycosylated secreted metalloproteinases. Our in-house QC SDS-PAGE confirms >90% purity at this apparent size, so a broad band in that window is expected, not a sign of degradation.

What is the processing state of recombinant ADAMTS-18 — is it the pro-form or mature active enzyme?

This preparation is produced as the active, processed form rather than the latent zymogen. HEK293 expression and secretion allow furin-like pro-protein convertases endogenous to the host cells to cleave the propeptide, releasing the mature metalloproteinase domain. The resulting recombinant retains the catalytic metalloproteinase domain along with its disintegrin-like, thrombospondin motif, cysteine-rich, and spacer domains. If your experiment specifically requires the pro-form or a defined truncation, contact us — but for enzymatic activity assays and most ECM remodelling studies, this active form is the appropriate starting material.

What substrates does recombinant ADAMTS-18 cleave, and how do I set up an activity assay?

Fibronectin is the best-characterised direct substrate: ADAMTS-18 cleaves fibronectin and negatively regulates fibronectin fibrillogenesis (Barbiera et al., 2025, J Biol Chem). For a cleavage activity assay, incubate recombinant ADAMTS-18 (0.5–2 µg) with purified fibronectin (5–20 µg) in assay buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl2) at 37°C for 4–18 hours, then resolve by SDS-PAGE and stain or blot for fibronectin fragmentation. Fluorogenic peptide substrates validated for other ADAMTS members (e.g., QELYMSMPD-based peptides) may also be screened, though fibronectin remains the only biochemically validated substrate for ADAMTS-18 to date.

What buffer conditions are optimal for ADAMTS-18 enzymatic activity, and does calcium matter?

As an astacin-clan metalloproteinase, ADAMTS-18 requires Ca²⁺ for both structural stability and catalytic activity. The storage and assay buffer — 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl2 — is formulated to maintain this requirement. Avoid EDTA- or EGTA-containing buffers, as chelation of Zn²⁺ at the active site and Ca²⁺ from structural sites will abolish activity. If your downstream assay includes protease inhibitor cocktails, verify they are EDTA-free. ZnCl2 supplementation (1–10 µM) can be added to assay buffer if activity appears suboptimal, though it is not routinely necessary at the recommended working concentrations.

What starting concentration should I use for recombinant ADAMTS-18 in an ECM remodeling assay?

For fibronectin cleavage and ECM-remodelling experiments, a practical starting range is 0.2–1 µg/mL (roughly 1.3–6.7 nM based on ~150 kDa apparent MW). Titrate upward if cleavage is incomplete after 18 hours at 37°C. For cell-based assays measuring fibronectin fibrillogenesis suppression, published work suggests nanomolar concentrations are sufficient to observe significant inhibition of matrix assembly. Keep working dilutions in the supplied storage buffer to maintain the 5 mM CaCl2 and 10% glycerol that stabilise the enzyme. Avoid diluting below 10 µg/mL in stock before aliquoting, as surface adsorption can cause activity loss at very low concentrations.

Can I use recombinant ADAMTS-18 as a positive control for Western blot with the matched rabbit polyclonal antibody RP-ADAMTS18?

Yes — this is one of the primary design intentions for pairing REC-ADAMTS18 with antibody RP-ADAMTS18. Load 50–200 ng of recombinant ADAMTS-18 per lane under reducing conditions; the antibody should detect the glycosylated band in the 150–175 kDa range. RP-ADAMTS18 is a rabbit polyclonal validated in-house for Western blot, making this recombinant a reliable, identity-confirmed positive control band. This is particularly useful when running lysates from tissues or cell lines where endogenous ADAMTS-18 expression is low or variable. See the RP-ADAMTS18 product page at /anti-adamts-18-rabbit-polyclonal-antibody for recommended antibody dilutions.

How much recombinant ADAMTS-18 should I load per lane for Western blot positive control to avoid oversaturation?

Start with 100 ng per lane; this is generally sufficient for detection with RP-ADAMTS18 at standard dilutions (1:500–1:2,000) without oversaturating the signal. If your film or digital imager is particularly sensitive, titrate down to 25–50 ng. Because ADAMTS-18 runs as a diffuse glycosylated band (~150–175 kDa), signal spread across a wider MW range means you may need slightly more material than you would for a sharp, non-glycosylated recombinant of the same mass. Include this lane alongside your experimental lysates to confirm antibody specificity and confirm correct band identification in complex samples.

How should I store and handle recombinant ADAMTS-18 to preserve enzymatic activity long-term?

Store at -20°C in single-use aliquots immediately upon receipt. The supplied buffer — 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 5 mM CaCl2, 10% glycerol — is formulated for freeze-thaw stability, but repeated cycling will degrade activity. Avoid freeze-thaw more than once. On the day of use, thaw on ice and dilute directly into your assay buffer; do not leave the working solution at room temperature for extended periods. Aliquot volume should match your typical experiment: 5–10 µg aliquots are practical for most activity assays. Under these conditions, stored material retains activity for up to 12 months at -20°C.

Validation imagery coming soon

Western blot validation figures for REC-ADAMTS18 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →